In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 4, 2008, Pages 1269-1277

  Meneceur, Pascale ^a   Bouldouyre, Marie Anne ^a   Aubert, Dominique ^c   Villena, Isabelle ^c   Menotti, Jean ^a,b   Sauvage, Virginie ^c   Garin, Jean François ^a,b   Derouin, Francis ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; CYTOCHROME B; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; PYRIMETHAMINE; SULFADIAZINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TOXOPLASMA GONDII;

ANIMALS; ANTIPROTOZOAL AGENTS; ATOVAQUONE; GENOTYPE; HUMANS; INHIBITORY CONCENTRATION 50; PARASITIC SENSITIVITY TESTS; PYRIMETHAMINE; SULFADIAZINE; TOXOPLASMA;

EID: 42049118031     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01203-07     Document Type: Article

References (49)

1. Ajzenberg, D., N. Cogne, L. Paris, M. H. Bessieres, P. Thulliez, D. Filisetti, H. Pelloux, P. Marty, and M. L. Dardé. 2002. Genotype of 86 Toxoplasma gondii isolates associated with human congenital toxoplasmosis, and correlation with clinical findings. J. Infect. Dis. 186:684-689.
2. Ajzenberg, D., A. Dumetre, and M. L. Dardé. 2005. Multiplex PCR for typing strains of Toxoplasma gondii. J. Clin. Microbiol. 43:1940-1943.
3. Allegra, C. J., J. A. Kovacs, J. C. Drake, J. C. Swan, B. A. Chabner, and H. Masur. 1987. Potent in vitro and in vivo anti Toxoplasma activity of the lipid-soluble antifolate trimetrexate. J. Clin. Investig. 79:478-482.
4. Araujo, F. G., J. Huskinson, and J. S. Remington. 1991. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob. Agents Chemother. 35:293-299.
5. Araujo, F. G., J. Huskinson-Mark, W. E. Gutteridge, and J. S. Remington. 1992. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob. Agents Chemother. 36:326-330.
6. Aspinall, T. V., D. H. Joynson, E. Guy, J. E. Hyde, and P. F. Sims. 2002. The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis. J. Infect. Dis. 185: 1637-1643.
7. Baatz, H., A. Mirshahi, J. Puchta, H. Gumbel, and L. O. Hattenbach. 2006. Reactivation of Toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient. Ocul. Immunol. Inflamm. 14:185-187.
8. Cassaing, S., M. H. Bessieres, A. Berry, A. Berrebi, R. Fabre, and J. F. Magnaval. 2006. Comparison between two amplification sets for molecular diagnosis of toxoplasmosis by real-time PCR. J. Clin. Microbiol. 44:720-724.
9. Chirgwin, K., R. Hafner, C. Leport, J. Remington, J. Andersen, E. M. Bosler, C. Roque, N. Rajicic, V. McAuliffe, P. Morlat, D. T. Jayaweera, J. L. Vildé, B. J. Luft, et al. 2002. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome. Clin. Infect. Dis. 34: 1243-1250.
10. Cook, M. K. 1958. The development of a pyrimethamine-resistant line of Toxoplasma under in vitro conditions. Am. J. Trop. Med. 7:400-402.
11. Corvaisier, S., B. Charpiat, C. Mounier, M. Wallon, G. Leboucher, M. Al Kurdi, J. F. Chaulet, and F. Peyron. 2004. Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis. Antimicrob. Agents Chemother. 48:3794-3800.
12. Dannemann, B., J. A. McCutchan, D. Israelski, D. Antoniskis, C. Leport, B. Luft, J. Nussbaum, N. Clumeck, P. Morlat, J. Chiu, et al. 1992. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann. Intern. Med. 116:33-43.
13. Derouin, F., and C. Chastang. 1988. Enzyme immunoassay to assess effect of antimicrobial agents on Toxoplasma gondii in tissue culture. Antimicrob. Agents Chemother. 32:303-307.
14. Derouin, F., and C. Chastang. 1989. In vitro effects of folate inhibitors on Toxoplasma gondii. Antimicrob. Agents Chemother. 33:1753-1759.
15. Donald, R. G., and D. S. Roos. 1993. Stable molecular transformation of Toxoplasma gondii: a selectable dihydrofolate reductase-thymidylate synthase marker based on drug-resistance mutations in malaria. Proc. Natl. Acad. Sci. USA 90:11703-11707.
16. El Hajj, H., M. Lebrun, S. T. Arold, H. Vial, G. Labesse, and J. F. Dubremetz. 2007. ROP18 is a rhoptry kinase controlling the intracellular proliferation of Toxoplasma gondii. PLoS Pathog. 3:e14.
17. Grigg, M. E., J. Ganatra, J. C. Boothroyd, and T. P. Margolis. 2001. Unusual abundance of atypical strains associated with human ocular toxoplasmosis. J. Infect. Dis. 184:633-639.
18. Harris, C., M. P. Salgo, H. B. Tanowitz, and M. Wittner. 1988. In vitro assessment of antimicrobial agents against Toxoplasma gondii. J. Infect. Dis. 157:14-22.
19. Howe, D. K., and L. D. Sibley. 1995. Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease. J. Infect. Dis. 172:1561-1566.
20. Jacobson, J. M., M. Davidian, P. M. Rainey, R. Hafner, R. H. Raasch, and B. J. Luft. 1996. Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. Antimicrob. Agents Chemother. 40:1360-1365.
21. Katlama, C., B. Mouthon, D. Gourdon, D. Lapierre, F. Rousseau, et al. 1996. Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. AIDS 10:1107-1112.
22. Kaufman, H. E., J. S. Remington, M. L. Melton, and L. Jacobs. 1959. Relative resistance of slow-growing strains of Toxoplasma gondii to pyrimethamine. AMA Arch. Ophthalmol. 62:611-615.
23. Kazanjian, P., W. Armstrong, P. A. Hossler, W. Burman, J. Richardson, C. H. Lee, L. Crane, J. Katz, and S. R. Meshnick. 2000. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J. Infect. Dis. 182:551-557.
24. Kazanjian, P., W. Armstrong, P. A. Hossler, C. H. Lee, L. Huang, C. B. Beard, J. Carter, L. Crane, J. Duchin, W. Burman, J. Richardson, and S. R. Meshnick. 2001. Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS. J. Infect. Dis. 183:819-822.
25. Kessl, J. J., K. H. Ha, A. K. Merritt, S. R. Meshnich, and B. L. Trumpower. 2006. Molecular basis of Toxoplasma gondii atovaquone resistance modeled in Saccharomyces cerevisiae. Mol. Biochem. Parasitol. 146:255-258.
26. Khan, A., C. Su, M. German, G. A. Storch, D. B. Clifford, and L. D. Sibley. 2005. Gcnotyping of Toxoplasma gondii strains from immunocompromised patients reveals high prevalence of type I strains. J. Clin. Microbiol. 43:5881-5887.
27. Khan, A., C. Jordan, C. Muccioli, A. L. Vallochi, L. V. Rizzo, R. Belfort, Jr., R. W. Vitor, C. Silveira, and L. D. Sibley. 2006. Genetic divergence of Toxoplasma gondii strains associated with ocular toxoplasmosis, Brazil. Emerg. Infect. Dis. 12:942-949.
28. Kovacs, J. A., C. J. Allegra, J. Beaver, D. Boarman, M. Lewis, J. E. Parrillo, B. Chabner, and H. Masur. 1989. Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents. J. Infect. Dis. 160:312-320.
29. Luft, B. J., and J. S. Remington. 1992. Toxoplasmic encephalitis in AIDS. Clin. Infect. Dis. 15:211-222.
30. Massimine, K. M., L. T. Doan, C. A. Atreya, T. T. Stedman, K. S. Anderson, K. A. Joiner, and I. Coppens. 2005. Toxoplasma gondii is capable of exogenous folate transport. A likely expansion of the BT1 family of transmembrane proteins. Mol. Biochem. Parasitol. 144:44-54.
31. McFadden, D. C., F. Seeber, and J. C. Boothroyd. 1997. Use of Toxoplasma gondii expressing β-galactosidase for colorimetric assessment of drug activity in vitro. Antimicrob. Agents Chemother. 41:1849-1853.
32. McFadden, D. C., S. Tomavo, E. A. Berry, and J. C. Boothroyd. 2000. Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance. Mol. Biochem. Parasitol. 108:1-12.
33. McLeod, R., D. Mack, R. Foss, K. Boyer, S. Withers, S. Levin, J. Hubbell, and the Toxoplasmosis Study Group. 1992. Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Antimicrob. Agents Chemother. 36:1040-1048.
34. Montoya, J. G., and O. Liesenfeld. 2004. Toxoplasmosis. Lancet 363:1965-1976.
35. Nagesha, H. S., S. Din, G. J. Casey, A. I. Susanti, D. J. Fryauff, J. C. Reeder, and A. F. Cowman. 2001. Mutations in the pfmdr1, dhfr and dhps genes of Plasmodium falciparum are associated with in-vivo drug resistance in West Papua, Indonesia. Trans. R. Soc. Trop. Med. Hyg. 95:43-49.
36. Petersen, E. 2007. Prevention and treatment of congenital toxoplasmosis. Expert Rev. Anti Infect. Ther. 5:285-293.
37. Peyron, F., N. Eudes, F. de Monbrison, M. Wallon, and S. Picot. 2004. Fitness of Toxoplasma gondii is not related to DHFR single-nucleotide polymorphism during congenital toxoplasmosis. Int. J. Parasitol. 34:1169-1175.
38. Pfefferkorn, E. R., S. E. Borotz, and R. F. Nothnagel. 1992. Toxoplasma gondii: characterization of a mutant resistant to sulfonamides. Exp. Parasitol. 74:261-270.
39. Pfefferkorn, E. R., S. E. Borotz, and R. F. Nothnagel. 1993. Mutants of Toxoplasma gondii resistant to atovaquone (566C80) or decoquinate. J. Parasitol. 79:559-564.
40. Radke, J. R., B. Striepen, M. N. Guerini, M. E. Jerome, D. S. Roos, and M. W. White. 2001. Defining the cell cycle for the tachyzoite stage of Toxoplasma gondii. Mol. Biochem. Parasitol. 115:165-175.
41. Reynolds, M. G., J. Oh, and D. S. Roos. 2001. In vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductase. Antimicrob. Agents Chemother. 45:1271-1277.
42. Reynolds, M. G., and D. S. Roos. 1998. A biochemical and genetic model for parasite resistance to antifolates. Toxoplasma gondii provides insights into pyrimethamine and cycloguanil resistance in Plasmodium falciparum. J. Biol. Chem. 273:3461-3469.
43. Romand, S., M. Pudney, and F. Derouin. 1993. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob. Agents Chemother. 37:2371-2378.
44. Schmidt, D. R., B. Hogh, O. Andersen, J. Fuchs, H. Fledelius, and E. Petersen. 2006. The national neonatal screening programme for congenital toxoplasmosis in Denmark: results from the initial four years, 1999-2002. Arch. Dis. Child. 91:661-665.
45. Tomavo, S., and J. C. Boothroyd. 1995. Interconnection between organellar functions, development and drug resistance in the protozoan parasite Toxoplasma gondii. Int. J. Parasitol. 25:1293-1299.
46. Torres, R. A., W. Weinberg, J. Stansell, G. Leoung, J. Kovacs, M. Rogers, J. Scott, et al. 1997. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Clin. Infect. Dis. 24:422-429.
47. Trenque, T., N. Simon, I. Villena, C. Chemla, C. Quereux, B. Leroux, R. Jaussaud, G. Remy, D. Dupouy, H. Millart, J. M. Pinon, and S. Urien. 2004. Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis. Br. J. Clin. Pharmacol. 57:735-741.
48. Tsuchiya, S., M. Yamabe, Y. Yamaguchi, Y. Kobayashi, T. Konno, and K. Tada. 1980. Establishment and characterization of a human acute monocytoid leukemia cell line (THP-1). Int. J. Cancer 26:171-176.
49. Winstanley, P., S. Khoo, S. Szwandt, G. Edwards, E. Wilkins, J. Tija, R. Coker, W. McKane, N. Beeching, S. Watkin, and A. Breckenridge. 1995. Marked variation in pyrimethamine disposition in AIDS patients treated for cerebral toxoplasmosis. J. Antimicrob. Chemother. 36:435-439.